Home › Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety...
 

Keywords :   


Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety...

2015-02-27 16:20:00| Appliances - Topix.net

CAMBRIDGE, Mass. & STOCKHOLM-- -- Biogen Idec and Swedish Orphan Biovitrum AB today announced positive top-line results of the Kids B-LONG Phase 3 clinical study that evaluated the safety, efficacy and pharmacokinetics of ALPROLIXA [Coagulation Factor IX , Fc Fusion Protein] in children under age 12 with severe hemophilia B. ALPROLIX was generally well tolerated and no inhibitors were detected during the study.

Tags: positive safety announce efficacy

Category:Consumer Goods and Services

Latest from this category

All news
15.05Taxpayers face 23-minute wait for HMRC helplines
15.05ACCESS and Neusoft offer integrated in-vehicle solution
15.05Livepeer Studio cuts the cost of live streaming & transcoding
15.05More subscribers choose streaming with ads in Sweden
15.05Five more San Antonio TV stations launch NEXTGEN TV
15.05Liberty Latin America organic Video RGUs up 2,000 in 1Q 2024
15.05Dine and dash couple hit my pizzeria, says owner
15.05Dine and dash couple hit my pizzeria, says owner
Consumer Goods and Services »
15.05Relationship Reviews Strengthening the Partnership Between Manufacturer and Rep
15.05Taxpayers face 23-minute wait for HMRC helplines
15.05Farm Progress America, May 15, 2024
15.05Farm Progress America, May 15, 2024
15.05ACCESS and Neusoft offer integrated in-vehicle solution
15.05Livepeer Studio cuts the cost of live streaming & transcoding
15.05More subscribers choose streaming with ads in Sweden
15.05Five more San Antonio TV stations launch NEXTGEN TV
More »